Results 101 to 110 of about 14,657 (135)
Some of the next articles are maybe not open access.
Expert Opinion on Drug Safety, 2010
Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions.The incidence ...
Robert, Coleman +6 more
+6 more sources
Both bone metastases and fragility fractures due to bone loss result in considerable morbidity affecting quality of life and independence as well as placing complex demands on healthcare resources. Zoledronic acid is a widely used intravenous bisphosphonate that reduces this skeletal morbidity in both benign and malignant conditions.The incidence ...
Robert, Coleman +6 more
+6 more sources
Drugs, 2001
Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro.
S M, Cheer, S, Noble
openaire +2 more sources
Zoledronic acid (zoledronate) is a new generation bisphosphonate that inhibits osteoclast bone resorption. It was much more potent than other bisphosphonates at inhibiting 1,25-dihydroxyvitamin D3-induced hypercalcaemia in a rat model and calcium release in vitro.
S M, Cheer, S, Noble
openaire +2 more sources
Zoledronic Acid and Angiogenesis
Clinical Cancer Research, 2007To the Editors: In a recent issue of Clinical Cancer Research , Santini and co-workers ([1][1]) assert that zoledronic acid (ZA) may inhibit several antiangiogenic-related cascades and its metronomic administration could represent a new potential therapy targeting the endothelial-tumor ...
Gianluigi, Ferretti +6 more
openaire +2 more sources
Expert Opinion on Drug Safety, 2007
Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and ...
openaire +2 more sources
Zoledronic acid has been marketed for the past 5 years for the treatment of hypercalcemia of malignancy and malignant bone disease in patients with multiple myeloma or a broad range of solid tumors. The safety profile of zoledronic acid in this patient population is well established from the databases of several large, randomized, Phase III trials and ...
openaire +2 more sources